Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
about
Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)Regulatory T Cell Modulation by CBP/EP300 Bromodomain InhibitionDiscovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration AnalysisEpigenetic modulators as therapeutic targets in prostate cancerAcetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and CancerCBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine AcetylationTargeting the Bromome: are we there yet?Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals.Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.Epigenetic Strategies to Boost Cancer Immunotherapies.Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.The Role of Histone Protein Modifications and Mutations in Histone Modifiers in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.Selective targeting of Bromodomains of the Bromodomain-PHD Fingers family impairs osteoclast differentiation.Progress in the Development of non-BET Bromodomain Chemical Probes.Epigenomic regulation of oncogenesis by chromatin remodeling.Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myelomaEpigenetic regulation of cardiac fibrosis.Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire.Selective targeting of epigenetic reader domains.Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology.Bromodomain inhibitors and cancer therapy: From structures to applications.Allosteric regulation of epigenetic modifying enzymes.Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation.BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression.Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasisIdentification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.Protein dynamics and structural waters in bromodomains.Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.Chemical probes and inhibitors of bromodomains outside the BET family.Peptidomimetic blockade of MYB in acute myeloid leukemia.CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion.Cation-π interactions in CREBBP bromodomain inhibition: an electrostatic model for small-molecule binding affinity and selectivity.Beyond the BET Family: Targeting CBP/p300 with 4-Acyl Pyrroles.Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.
P2860
Q27644535-905BE895-7F50-4E5A-94BE-09E746845F23Q27644651-26F1310B-630E-4641-9CB6-085C47CAE9CFQ27728041-F8039E36-57CA-4579-A78B-62287515CB91Q28071912-D0CA1C22-DDD4-476C-9A09-7C2E325FAF91Q28076086-49CE6F05-4D68-454C-9CF4-237356BE1980Q28818241-E12AE6A6-9F11-49F1-9B0D-394A5E826ED5Q30489777-41951CDE-C326-4C05-8B55-E317AACB59FBQ33633254-7B55EFF8-7A17-4AFE-AA69-36E889F72F72Q33791305-4C74F63C-4B43-4B33-97FC-E7227E79179CQ33838340-12424FDC-3786-4269-9375-AD68F6236B27Q36012341-3BC1BFE7-A112-4373-8E24-60BA77565F34Q37223691-9E111823-376C-45EF-BC80-277D126CD4F4Q37334404-AD6CB9E3-69D0-47B6-A168-24AC6AC9A9B5Q37629537-B9D2A69A-B15A-4E0B-B80A-388D9C69428AQ37633585-5F3B9A0E-2E31-473B-978F-39EAA5FFA342Q38604141-82369D92-D7F3-40D0-8BA2-B9DE95FD0AC5Q38691377-4F878E99-3143-4C5B-AA50-35CA23F32618Q38709544-4251C97B-918E-4AFC-ADA5-0396E5644329Q38729035-8F6DACF5-1FD8-47DA-829C-C64A06E5473EQ38733315-656490F9-ACB9-4D67-8452-A275E43392F1Q38741165-FA57B71A-D6A2-405B-88FD-9054661D2C6CQ38744593-8B02D1AE-A67C-494A-8FB9-2A3835A59E65Q38748150-AE4E90EA-4DB3-47A1-8ED1-7D5A8618D64AQ38837561-AC133380-7F4D-4131-9378-1C872F1DDC8CQ39027056-22B0AAB3-8E1C-4B09-B932-86CD228C1CE0Q39423283-9BE553D3-886B-4E79-8791-0BF12531EE47Q39423291-FD690304-36E2-4416-B703-D2BF1A31E6E5Q39737405-1B401F76-6662-4EAC-A458-067B8F153552Q41534994-D904FF93-DA6E-40A7-9A75-F2ED8D2B79E7Q41895213-57716EB6-D223-4EF8-844E-5A35E9FBFBA1Q42320410-8B461390-7643-4AA8-A59E-4B6303CA0540Q42513461-E15A743D-9871-4C31-A8F7-322B39914B24Q44452823-692DC8F4-BF25-47CF-B2F9-FE9669A3CF76Q46985603-FF78DA16-28DD-43A2-8FA6-5BA010389C5BQ47128083-B35E868C-92FD-4BAD-9FBC-EE075179C21BQ47215625-73E00053-DBAB-4870-B048-52DA4AA0681DQ48014614-1E5B87A4-F25F-400B-AEDF-94E8739CDD0FQ48245176-C9450500-5232-40FB-824B-5A22EF2AB392Q48307308-6D5E8DD5-908F-45E7-B114-73EAB8BAC730Q49592738-F61333AA-067E-4132-A9DD-F2035E7EA409
P2860
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@ast
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@en
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@en-gb
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@nl
type
label
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@ast
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@en
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@en-gb
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@nl
prefLabel
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@ast
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@en
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@en-gb
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@nl
P2093
P2860
P50
P3181
P1433
P1476
Generation of a Selective Smal ...... omodomain for Leukemia Therapy
@en
P2093
Alison O'Mahony
Angeliki Thanasopoulou
Anthony Tumber
Chas Bountra
Christopher Wells
Clarence Yapp
Danette L Daniels
Duncan Hay
Julia Meier
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-15-0236
P407
P50
P577
2015-12-01T00:00:00Z